中外製薬（4519） – Notice of Changes in Representative Directors and Directors

February 3, 2022 Name of listed company: Chugai Pharmaceutical Co., Ltd. Code number: Head office: 4519 (1st Section of Tokyo Stock Exchange) 1-1, Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo President & CEO: Osamu Okuda Inquiries to: Toshiya Sasai Head of Corporate Communications Dept. Tel: +81-(0)3-3273-0554 Notice of Changes in Representative Directors and Directors Chugai Pharmaceutical Co., Ltd. (the “Company”) announces changes in Representative Directors and Directors with the resolution of the Board of Directors Meeting held on February 3, 2022, as described below. The changes will be formalized after the Annual General Meeting of Shareholders and the Board of Directors Meeting scheduled on March 29, 2022. 1. Change in Representative Directors (1) Reason for Change Since the conclusion of the strategic alliance agreement with Roche in 2001, the Company has been working diligently to establish a unique business model. In order to achieve sustainable growth and development of the Chugai group and further enhance the corporate value through promoting our growth strategy “TOP I 2030” under a new management structure in 2022, Tatsuro Kosaka, Representative Director and Chairman, and Motoo Ueno, Representative Director and Deputy Chairman will retire, and Executive Vice Presidents, Hisafumi Yamada and Toshiaki Itagaki will be appointed as Directors. (2) Retiring Representative Directors Current Title Representative Director, Chairman Representative Director, Deputy Chairman Name Tatsuro Kosaka Motoo Ueno * Tatsuro Kosaka and Motoo Ueno are expected to be appointed as Senior Advisors. ** Osamu Okuda is expected to be appointed as Chairman of the Board of Directors. (3) Effective Date March 29, 2022 2. Change in Directors (1) Newly Appointed Directors Name New Title Current Title Hisafumi Yamada Director, Executive Vice President Executive Vice President Supervisory responsibility for Project & Supervisory responsibility for Project & Lifecycle Management (R&D), Research, Lifecycle Management (R&D), Research, Translational Research, Clinical and Translational Research Development, and Pharmaceutical Technology Director, Executive Vice President Executive Vice President Chief Financial Officer (CFO) Chief Financial Officer (CFO) Supervisory responsibility for Finance & Supervisory responsibility for Finance & Accounting, Corporate Communication, and Accounting, Corporate Communication, Purchasing Purchasing, and Digital Transformation Head of Finance Supervisory Div. Head of Finance Supervisory Div. Toshiaki Itagaki (2) Effective Date March 29, 2022 ###